FDA expedites review of Biogen's multiple sclerosis drug

07/8/2009 | American City Business Journals

The FDA granted fast-track designation to Biogen Idec's PEGylated interferon beta-1a, a multiple sclerosis medicine. The drug's potential to treat patients with only one or two injections a month might have been a factor in the agency's decision. Biogen plans on "working closely with the FDA to expedite the compound's development and review process," a company official said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC